3 ASX 200 shares named as buys

Here are three buy-rated ASX 200 shares to look at…

| More on:
asx buy

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Looking for some ASX 200 shares to add to your portfolio? Then take a look at the three listed below.

Here's why they are rated as buys currently:

Aristocrat Leisure Limited (ASX: ALL)

The first ASX 200 share to look at is Aristocrat Leisure. It is one of the world's leading gaming technology companies. The last 12 months have been difficult for Aristocrat but it has bounced back strongly and looks well-positioned for growth. Especially now both its pokie machine and digital businesses are pulling together again. Citi is a fan of the company. It has a buy rating and $46.00 price target on its shares.

REA Group Limited (ASX: REA)

REA Group could be an ASX 200 share to consider. It is the leading player in real estate listings in the Australian market. This is a great position to be right now thanks to the housing market boom, which is underpinning solid listings growth. In addition to this, cost cutting, new revenue streams, price increases, and acquisitions look set to give its sales and earnings a boost in the coming years. Goldman Sachs is very bullish on REA Group. It recently put a buy rating and $198.00 price target on its shares.

ResMed Inc. (ASX: RMD)

Another ASX 200 share to look at is ResMed. It is one of the world's leading medical device companies with a focus on sleep disorders. ResMed has been tipped for further strong growth over the 2020s thanks to its enormous addressable market, its industry-leading technology, and its digital health ecosystem. In respect to the latter, the company's investment in digital health have given it an advantage over much of the competition and puts it in a strong position to benefit from the shift to home healthcare. Macquarie currently has an outperform rating and $34.85 price target on its shares.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended REA Group Limited and ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Growth Shares

Man pointing an upward line on a bar graph symbolising a rising share price.
Growth Shares

4 top ASX growth shares to buy and hold

Analysts think these stocks are in the buy zone right now.

Read more »

Young woman using computer laptop smiling in love showing heart symbol and shape with hands. as she switches from a big telco to Aussie Broadband which is capturing more market share
Growth Shares

Here are 4 exciting ASX growth stocks that brokers love in 2024

Brokers think investors should be snapping up these growth stocks.

Read more »

A girl is handed an oversized ice cream cone with lots of different flavours.
Growth Shares

How I'd use ASX growth shares to turn $1,000 into $10,000

Choosing the right growth shares can add plenty of bang to your buck.

Read more »

a man in a business suit points his finger amid a digitised map of the globe suspended in the air in front of him, complete with graphs, digital code and glyphs to indicate digital assets.
Investing Strategies

Future focus: How to diversify your portfolio with ASX AI ETFs

Looking for a simple and effective way to capitalise on the growth of AI technologies across global markets?

Read more »

chart showing an increasing share price
Growth Shares

Buy these excellent ASX growth shares for 15% to 20% returns

Analysts think big returns could be on the cards for owners of these shares.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Growth Shares

These ASX 200 growth shares could rise 12% to 30%

Analysts think big returns could be on offer from these shares.

Read more »

Man in an office celebrates at he crosses a finish line before his colleagues.
Growth Shares

Hoping to beat the ASX 200? I'd consider buying these 3 ASX shares

Analysts think these shares can outperform the market.

Read more »

a happy investor with a wide smile points to a graph that shows an upward trending share price
Growth Shares

5 top ASX growth shares to buy in April

Analysts think growth investors should be buying these shares.

Read more »